10x Genomics, Inc.

Laboratory Analytical Instruments

TXGStrained4 of 9 basics passed

$81.05

+4.88%

Market cap $10.6B

$81.05

+4.88%

Market cap $10.6B

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems.

It is a $10.6B technology company. Revenue shrank 4.3% over the last year, and it currently loses money.

Website: 10xgenomics.com
Location: Pleasanton, CA
Employees: 1 178
Sector: Technology
Founded: 2012

Share price · 3 years

$40.97 → $81.05+97.8%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $617M
Loss: spends more than it earns; -$75.1M
Free cash flow: cash left after running the business; $121M
Shares: up 13% since 2021 — dilution; 124.7M
Volatility: beta vs the market — under 1 swings less; 1.99

Revenue, last 7 years

52-week range

Low $11.47$81.05High $97.74

Today's price is 81% of the way from the year's low to its high.

Valuation vs own history

P/S

17.0×

P/B

12.7×

FCF yield

1.2%

Share of the last ~5 years that was pricier than today (unusually expensive vs its own history). Based on the daily valuation record.

Insider activity · 90 days

-$6.30Mnet selling

Purchases$0

Sales$6.30M

Insiders trading, last 14d0 buy · 0 sell

Standing in Technology

Size$10.6Btop 86%
Revenue growth+8%top 60%
Net margin-12%top 91%
Return on equity-9%top 91%

Ranked against 220 Technology companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Valuation, Growth, Profitability, Health, Quality and Moat lag behind.

Valuation30

P/E vs own historyn/a · 10/25
FCF yield1.1% · 5/25
P/S17.0x · 5/25
EV/EBITDAn/a · 10/25

Growth12

Revenue CAGR7.0% · 12/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROIC-5.8% · 0/25
ROE-9.3% · 0/25
Net margin-12.2% · 0/25
Operating margin-14.3% · 0/25

Health25

Altman Zn/a · 0/25
Current ratio5.69 · 25/25
Interest coverage-75.7x · 0/25
Net cash / debtn/a · 0/25

Quality35

Piotroski F4/9 · 10/25
Beneish M-2.94 · 25/25
FCF conversionn/a · 0/25
Margin stabilityσ 32.4% · 0/25

Moat25

ROIC >12% years0/7 yrs · 0/25
Median gross margin75.2% · 25/25
FCF-positive years1/7 yrs · 0/25
Worst-year net marginworst -181.6% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

Sep 12, 2019IPO
10x Genomics announced its initial public offering on September 12, 2019, raising $390M
2018Acquisition
The company announced its first acquisition, Epinomics, a biotechnology company focused on the…
2012Founded
10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment…

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$5 319 today — price return only

$642.8M revenue in FY2025

1 178 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (69.6%)
Strong cash conversion — FCF is 19.7% of revenue

Watch-outs

Revenue shrinking 4.3% year over year
Not profitable — 12.2% net margin
Thin interest coverage (-75.7×)
Loss-making in 7 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

4 of 9 checks passed

Revenue growing — the company sells more than a year ago-4.3% YoY
Profitable — makes more than it spends-$75.1M TTM
Profit growing — earnings are higher than last year+76.2% YoY
Generates cash — cash left after running and investing$121M TTM
Debt under control — could handle its obligationscurrent ratio 5.69
Established company — not a micro-cap — lower blow-up risk$10.6B market cap
Not printing shares — share count not ballooning — you keep your slice+13.1% shares over ~5y
Proven track record — years of profitability behind it0/7 profitable years
Financially stable — balance sheet not near distresshealth score 25/100
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparison10x Genomics, Inc. vs 6 largest technology peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
TXG this company	$10.6B	—	-4.3%	-12.2%	Strained
NVDA Nvidia Corp	$5.5T	28.6	+83.4%	63.7%	Mixed
AAPL Apple Inc.	$4.9T	38.1	+14.2%	27.6%	Strong
GOOGL Alphabet Inc.	$4.3T	17.6	+20.1%	54.8%	Mixed
MSFT Microsoft Corp	$4.0T	29.7	+17.8%	40.3%	Strong
SPCX Space Exploration Technologies Corp.	$2.1T	—	+33.2%	-34.0%	Strained
META Meta Platforms, Inc.	$1.8T	26.9	+27.7%	29.8%	Mixed

Head-to-head: TXG vs NVDA · TXG vs AAPL · TXG vs GOOGL

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 5Buy 4Hold 11

Appendix · Financial records

The full statements behind this CV, FY2019–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $617M · net income -$75.1M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$617M

YoY -4.3%

Net income (TTM)

-$75.1M

Margin -12.2%

Gross margin

69.6%

Operating margin

-14.3%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.3	0.5	0.5	0.6	0.6	0.6
Gross profit	0.2	0.4	0.4	0.4	0.4	0.4
Operating income (EBIT)	-0.5	-0.1	-0.2	-0.3	-0.2	-0.1
Net income	-0.5	-0.1	-0.2	-0.3	-0.2	-0.0
EPS (diluted)	—	-0.53	-1.46	-2.18	-1.52	-0.35

Cash flowFree cash flow $121M · operating cash flow $127M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$121M

Margin 19.7%

Operating cash flow (TTM)

$127M

FCF margin

19.7%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	-0.2	-0.0	-0.0	-0.0	0.0	0.1
Capital expenditure	-0.0	-0.1	-0.1	-0.0	-0.0	-0.0
Free cash flow	-0.3	-0.1	-0.2	-0.1	-0.0	0.1
FCF margin	-85.2%	-25.0%	-32.0%	-10.3%	-0.9%	20.2%

Balance sheetAssets $1.04B · debt n/a (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $1.04B of assets is financed

24%

76%

Liabilities $245M — borrowed moneyEquity $796M — owners' stake

Debt repayment

0.0 yrs

Years of free cash flow to clear net debt

Interest coverage

-75.7x

EBIT ÷ interest expense

ROE

-9.3%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.7	0.6	0.2	0.0	0.0	0.0
Total assets	0.9	1.0	1.0	1.0	0.9	1.0
Total liabilities	0.2	0.2	0.2	0.2	0.2	0.2
Total debt	0.0	—	—	—	—	—
Equity	0.7	0.8	0.8	0.7	0.7	0.8
Net debt	-0.7	—	—	—	—	—

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of TXG on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $81.05 · market cap $10.6B.